On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...

Sun Pharmaceutical and its Taro Pharmaceutical subsidiary are washing their hands of another segment of a years-long ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment  a thumbs down, Europe’s Committee for Medicinal Products ...

GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about ...

Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

With an uptick in licensing deals and promising data emerging from China-based biopharmas, especially in oncology, it’s clear ...

Sarepta would need to conduct new analyses to validate the safety of Elevidys—which has had U.S. shipments paused by the ...